Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(8%)
Results Posted
0%(0 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
4
31%
Ph phase_2
3
23%
Ph phase_4
2
15%
Ph early_phase_1
1
8%
Ph phase_1
3
23%

Phase Distribution

4

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
4(30.8%)
Phase 4Post-market surveillance
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)
Other(4)

Detailed Status

Completed5
unknown4
Terminated2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 13 (23.1%)
Phase 23 (23.1%)
Phase 34 (30.8%)
Phase 42 (15.4%)

Trials by Status

completed538%
enrolling_by_invitation18%
unknown431%
recruiting18%
terminated215%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13